The Medical Letter on Drugs and Therapeutics
Drugs for MRSA Skin and Soft-Tissue Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Methicillin-resistant Staphylococcus aureus (MRSA), which was traditionally a nosocomially-acquired organism but now frequently occurs in the absence of healthcare exposure, is the predominant cause of suppurative skin and soft-tissue infections in many parts of the US.1,2 Community-associated MRSA usually causes furunculosis, purulent cellulitis, and abscesses, but necrotizing fasciitis, necrotizing pneumonia, and sepsis can also occur.

ANTIMICROBIAL SUSCEPTIBILITY — Community-associated MRSA strains have been susceptible in vitro to vancomycin, daptomycin, and linezolid, and usually to clindamycin, trimethoprim/sulfamethoxazole (TMP/SMX), and tetracyclines.3 Nosocomial strains of MRSA are often resistant to clindamycin, tetracyclines, and TMP/SMX. Resistance to fluoroquinolones is common and is increasing in both nosocomial ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for MRSA Skin and Soft-Tissue Infections
Article code: 1442b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian